Innovating Works

CAtALySt

Financiado
NeurescueTM Computer controlled aortic occlusion device for the treatment of c...
NeurescueTM Computer controlled aortic occlusion device for the treatment of cardiac arrest With a worldwide incidence expected to increase from 9,23 million cases by 2020 to 10,89 million cases by 2030, Sudden Cardiac Arrests (SCA) episodes are today recognized as a public health problem leading to severe brain tissue d... With a worldwide incidence expected to increase from 9,23 million cases by 2020 to 10,89 million cases by 2030, Sudden Cardiac Arrests (SCA) episodes are today recognized as a public health problem leading to severe brain tissue damage with survival rates below 10%. Neurescue Aps (NEUR) proposes to address the SCA burden by bringing to light a game changing solution - NeurescueTM – capable of extending the critical time window necessary to bring a SCA patient back to normal heart function, and therefore holding the potential to radically improve the emergency assistance provided to SCA patients, allowing for 20- 40% of increase in the survival rate of SCA patients. Due to an algorithm-run sensor technology which enables a safe and accurate computer-controlled aortic occlusion, NeurescueTM is a portable medical device that, not only increases the blood perfusion pressure necessary for vital organs preservation (i.e. brain and heart), but also works in synergy with standard resuscitation procedures increasing their probability of success. NeurescueTM is the only device in the market that combines portability with the accuracy required for a safe medical intervention (i.e. aorta occlusion) to SCA patients both inside and outside the hospital premises. With a price-competitive technology and with an unrivalled value proposition, NEUR is in a strong position to build a profitable business. Building on the project activities, NeurescueTM the device is projected to be ready for commercial roll-out by 2021 with a predicted total aggregated revenue for the company of over €234M throughout the 5 years post- project. CAtALySt project aims to surpass the main market barriers associated with the market introduction of NeurescueTM, namely obtaining FDA clearance, gathering data for CE-marking and broad clinical demonstration for market awareness and to ensure end-user medical adoption. Pre-clinical validation will be completed with Heidelberg University Hospital in Germany on 10 in-hospital cardiac arrest patients, and with MemorialCare Heart Institure in Los Angeles, USA on 10 in-hospital cardiac arrest patients. ver más
31/01/2023
Neurescue
2M€
Duración del proyecto: 54 meses Fecha Inicio: 2018-07-02
Fecha Fin: 2023-01-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2023-01-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020: SME instrument
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 2M€
Líder del proyecto
NEURESCUE APS No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5